Article citationsMore>>

Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J.C., Weisman, J., Pariser, D., et al. (2017) Long-Term Management of Moderate-to-Severe Atopic Dermatitis with Dupilumab and Concomitant Topical Corticosteroids (LIBERTY AD CHRONOS): A 1-Year, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial. The Lancet, 389, 2287-2303.
https://doi.org/10.1016/s0140-6736(17)31191-1

has been cited by the following article:

• TITLE: A Case of Refractory Facial Erythema in a Patient with Atopic Dermatitis

  AUTHORS: Zhou Yan, Anyu Zheng, Xiaoyong Zhou

  KEYWORDS: Atopic Dermatitist, Facial Erythema, Dupilumab, Upadacitinib Sustained-Release Tablets, Cyclosporine

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.14 No.8, August 18, 2025

  ABSTRACT: A 22-year-old female patient had recurrent red rashes on the peripheral skin with itching for more than 10 years. Specialized examination revealed dry and rough skin on the head, face, limbs, and trunk. Multiple hypertrophic plaques of varying sizes, covered with a few scales, were observed on the dorsa of hands, palms, extremities (elbow fossae, popliteal fossae) and dorsa of both feet. Diagnosis: Atopic Dermatitis (moderate to severe). Treatment: The patient showed a poor response to conventional therapy. After treatment with dupilumab, Atopic Dermatitis symptoms improved significantly. However, facial erythema and swelling were aggravated after six months of this regimen. Upon re-evaluation, dupilumab was discontinued. Oral cyclosporine was administered to alleviate facial erythema, followed by maintenance therapy with upadacitinib sustained-release tablets (15 mg/d), which has not recurred.